S260: IMMUNE EFFECTOR CELL ASSOCIATED HEMATOTOXICITY (ICAHT) FOLLOWING CAR T-CELL THERAPY: INTERNATIONAL SURVEY AND CONSENSUS GUIDELINES ON ITS GRADING, DIAGNOSIS, AND MANAGEMENT ON BEHALF OF EHA AND EBMT

• Kai Rejeski,
• Raffaella Greco,
• Francesco Onida,
• Isabel Sánchez-Ortega,
• Chiara Bonini,
• Anna Sureda,
• John Gribben,
• Ibrahim Yakoub-Agha,
• Marion Subklewe

Affiliations

Kai Rejeski

1 University Hospital, LMU Munich, Department of Medicine III – Hematology/Oncology, Munich, Germany

Raffaella Greco

2 IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Unit of Hematology and Bone Marrow Transplantation, Milan, Italy

Francesco Onida

3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Hematology and BMT Unit, Milan, Italy

Isabel Sánchez-Ortega

4 EBMT, Executive Office, Barcelona, Spain

Chiara Bonini

5 Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele Scientific Institute, Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, Milan, Italy

Anna Sureda

6 Institut Català d’Oncologia-Hospital Duran i Reynals, Barcelona, Spain

John Gribben

7 Barts Cancer Institute, Queen Mary University London, Centre for Haemato-Oncology, London, United Kingdom

Ibrahim Yakoub-Agha

8 CHU de Lille, Lille, France

Marion Subklewe

1 University Hospital, LMU Munich, Department of Medicine III – Hematology/Oncology, Munich, Germany